rasagiline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
monoamine oxydase (MAO)-inhibitors type B	3521	136236-51-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: TVP-1022 rasagiline hydrochloride rasagiline azilect (R)-(+)-Rasagiline rasagiline mesylate TV-1030 rasagiline mesilate	Rasagiline is a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson's disease. The results of a clinical trial designed to examine the effects of rasagiline tablets on blood pressure when it is administered with increasing doses of tyramine indicates the functional selectivity can be incomplete when healthy subjects ingest large amounts of tyramine while receiving recommended doses of rasagiline tablets. The selectivity for inhibiting MAO-B diminishes in a dose-related manner. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline’s beneficial effects seen in models of dopaminergic motor dysfunction. Molecular weight: 171.24 Formula: C12H13N CLOGP: 2.34 LIPINSKI: 0 HAC: 1 HDO: 1 TPSA: 12.03 ALOGS: -3.84 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

TVP-1022
rasagiline hydrochloride
rasagiline
azilect
(R)-(+)-Rasagiline
rasagiline mesylate
TV-1030
rasagiline mesilate

Rasagiline is a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson's disease. The results of a clinical trial designed to examine the effects of rasagiline tablets on blood pressure when it is administered with increasing doses of tyramine indicates the functional selectivity can be incomplete when healthy subjects ingest large amounts of tyramine while receiving recommended doses of rasagiline tablets. The selectivity for inhibiting MAO-B diminishes in a dose-related manner. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline’s beneficial effects seen in models of dopaminergic motor dysfunction.

Molecular weight: 171.24
Formula: C12H13N
CLOGP: 2.34
LIPINSKI: 0
HAC: 1
HDO: 1
TPSA: 12.03
ALOGS: -3.84
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	mg	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	36 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	20 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company
March 23, 2018	PMDA	Takeda Pharmaceutical Company Limited
May 16, 2006	FDA	TEVA
Feb. 21, 2005	EMA	TEVA B.V.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hallucination	286.15	23.93	124	5396	54693	63428809
Dyskinesia	229.86	23.93	91	5429	31911	63451591
Hallucination, visual	193.27	23.93	70	5450	19228	63464274
Serotonin syndrome	153.07	23.93	66	5454	28616	63454886
On and off phenomenon	132.60	23.93	31	5489	1804	63481698
Fall	129.18	23.93	164	5356	392170	63091332
Freezing phenomenon	105.28	23.93	24	5496	1248	63482254
Bradykinesia	88.11	23.93	28	5492	5160	63478342
Delusion	75.22	23.93	31	5489	11986	63471516
Tremor	70.08	23.93	71	5449	132168	63351334
Pleurothotonus	67.74	23.93	17	5503	1332	63482170
Drug interaction	67.62	23.93	91	5429	229040	63254462
Muscle rigidity	63.05	23.93	27	5493	11473	63472029
Orthostatic hypotension	62.47	23.93	39	5481	36121	63447381
Stoma site discharge	60.10	23.93	16	5504	1582	63481920
Confusional state	49.60	23.93	80	5440	236300	63247202
Gambling disorder	49.30	23.93	13	5507	1239	63482263
Sudden onset of sleep	48.82	23.93	11	5509	542	63482960
Akinesia	46.20	23.93	13	5507	1580	63481922
Impulse-control disorder	44.92	23.93	11	5509	779	63482723
Anxiety	40.75	23.93	70	5450	217471	63266031
Compulsive shopping	40.28	23.93	10	5510	749	63482753
Stoma site erythema	39.94	23.93	11	5509	1236	63482266
Hypersexuality	38.66	23.93	9	5511	513	63482989
Colitis microscopic	35.54	23.93	17	5503	9322	63474180
Serum serotonin increased	34.83	23.93	7	5513	198	63483304
Dystonia	34.69	23.93	19	5501	13800	63469702
Coronary artery dissection	34.18	23.93	9	5511	853	63482649
Fracture	33.50	23.93	21	5499	19563	63463939
Altered state of consciousness	33.28	23.93	23	5497	25207	63458295
Labelled drug-drug interaction medication error	32.47	23.93	18	5502	13381	63470121
Gait disturbance	31.76	23.93	57	5463	183121	63300381
Stoma site hypergranulation	31.68	23.93	7	5513	315	63483187
Agitation	31.44	23.93	32	5488	59725	63423777
Stoma site infection	29.92	23.93	8	5512	804	63482698
Dementia	29.28	23.93	19	5501	18775	63464727
Compulsive hoarding	29.25	23.93	5	5515	56	63483446
Psychotic symptom	28.89	23.93	9	5511	1552	63481950
Choking	28.78	23.93	15	5505	9864	63473638
Balance disorder	28.66	23.93	36	5484	84386	63399116
Stoma site extravasation	26.18	23.93	6	5514	319	63483183
Device dislocation	26.09	23.93	20	5500	25685	63457817
Nocturia	25.56	23.93	13	5507	8128	63475374
Hypertensive crisis	25.16	23.93	16	5504	15270	63468232
Resting tremor	25.16	23.93	7	5513	816	63482686
Cerebral atrophy	24.85	23.93	11	5509	5055	63478447
Presyncope	24.72	23.93	20	5500	27765	63455737
Wrong device used	24.30	23.93	4	5516	35	63483467

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hallucination	472.50	24.21	235	8153	51263	34897280
Impulse-control disorder	304.08	24.21	69	8319	1232	34947311
Dyskinesia	293.59	24.21	131	8257	22282	34926261
Hypersexuality	212.36	24.21	53	8335	1440	34947103
Hallucination, visual	189.07	24.21	90	8298	17701	34930842
On and off phenomenon	180.86	24.21	52	8336	2445	34946098
Fall	169.98	24.21	225	8163	202660	34745883
Gambling disorder	163.52	24.21	44	8344	1616	34946927
Freezing phenomenon	147.94	24.21	40	8348	1496	34947047
Orthostatic hypotension	130.89	24.21	80	8308	25839	34922704
Confusional state	128.40	24.21	165	8223	143995	34804548
Dopamine dysregulation syndrome	116.39	24.21	26	8362	430	34948113
Delusion	104.70	24.21	54	8334	12581	34935962
Serotonin syndrome	86.72	24.21	56	8332	19877	34928666
Abnormal behaviour	75.30	24.21	56	8332	24913	34923630
Bradykinesia	71.61	24.21	29	8359	3864	34944679
Resting tremor	66.79	24.21	18	8370	664	34947879
Sudden onset of sleep	65.97	24.21	16	8372	384	34948159
Muscle rigidity	62.27	24.21	36	8352	10482	34938061
Stoma site discharge	60.71	24.21	19	8369	1194	34947349
Somnolence	60.51	24.21	101	8287	111015	34837528
Dystonia	58.63	24.21	35	8353	10810	34937733
Tremor	57.38	24.21	84	8304	82503	34866040
Compulsive shopping	55.73	24.21	14	8374	390	34948153
Embedded device	53.36	24.21	13	8375	318	34948225
Cogwheel rigidity	50.64	24.21	17	8371	1335	34947208
Cognitive disorder	50.26	24.21	47	8341	28646	34919897
Device dislocation	49.71	24.21	26	8362	6223	34942320
Stoma site erythema	49.63	24.21	15	8373	838	34947705
Colitis microscopic	48.52	24.21	19	8369	2318	34946225
Stereotypy	47.00	24.21	14	8374	744	34947799
Psychomotor hyperactivity	46.74	24.21	29	8359	9593	34938950
Balance disorder	44.88	24.21	52	8336	40602	34907941
Jealous delusion	43.94	24.21	11	8377	302	34948241
Akinesia	42.69	24.21	17	8371	2167	34946376
Hyperkinesia	42.52	24.21	16	8372	1752	34946791
Supine hypertension	42.44	24.21	11	8377	348	34948195
Agitation	42.20	24.21	60	8328	57339	34891204
Marasmus	41.27	24.21	12	8376	586	34947957
Dementia	39.57	24.21	30	8358	13718	34934825
Aggression	38.33	24.21	47	8341	38917	34909626
Therapeutic product effect variable	37.43	24.21	16	8372	2440	34946103
Gait disturbance	36.78	24.21	70	8318	85070	34863473
Oesophageal achalasia	36.61	24.21	10	8378	388	34948155
Sleep disorder	35.75	24.21	41	8347	31647	34916896
Mesenteric artery thrombosis	35.42	24.21	10	8378	439	34948104
Obsessive-compulsive personality disorder	34.86	24.21	8	8380	150	34948393
Rapid eye movement sleep behaviour disorder	34.76	24.21	8	8380	152	34948391
Paraphilia	34.14	24.21	7	8381	75	34948468
Anticholinergic syndrome	32.40	24.21	12	8376	1257	34947286
Dysphagia	31.64	24.21	55	8333	62326	34886217
Autonomic nervous system imbalance	30.44	24.21	14	8374	2537	34946006
Hyperthermia	30.26	24.21	23	8365	10554	34937989
Psychotic disorder	29.91	24.21	33	8355	24419	34924124
Toxicity to various agents	29.70	24.21	6	8382	200356	34748187
Restlessness	28.79	24.21	33	8355	25449	34923094
Nocturia	28.76	24.21	22	8366	10188	34938355
Blood lactic acid	28.63	24.21	8	8380	338	34948205
Mobility decreased	27.48	24.21	35	8353	30093	34918450
Fracture	26.74	24.21	18	8370	6831	34941712
Disturbance in attention	26.65	24.21	32	8356	25913	34922630
Impulsive behaviour	26.22	24.21	12	8376	2150	34946393
Micturition disorder	25.77	24.21	12	8376	2236	34946307
Binge eating	25.73	24.21	6	8382	121	34948422
Neuroleptic malignant syndrome	25.10	24.21	26	8362	17908	34930635
Thunderclap headache	24.94	24.21	6	8382	139	34948404
Sleep attacks	24.66	24.21	6	8382	146	34948397
Prescribed underdose	24.62	24.21	19	8369	8914	34939629

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hallucination	581.13	20.29	273	11493	85472	79647150
Dyskinesia	419.47	20.29	179	11587	44594	79688028
Hallucination, visual	336.99	20.29	140	11626	32589	79700033
Impulse-control disorder	282.89	20.29	63	11703	1711	79730911
On and off phenomenon	269.79	20.29	68	11698	3172	79729450
Fall	245.91	20.29	329	11437	487300	79245322
Freezing phenomenon	209.21	20.29	50	11716	1864	79730758
Orthostatic hypotension	201.55	20.29	117	11649	56047	79676575
Serotonin syndrome	197.45	20.29	107	11659	44920	79687702
Hypersexuality	173.89	20.29	42	11724	1638	79730984
Gambling disorder	166.07	20.29	42	11724	1984	79730638
Delusion	140.90	20.29	66	11700	20357	79712265
Dopamine dysregulation syndrome	131.57	20.29	27	11739	490	79732132
Confusional state	122.12	20.29	189	11577	317808	79414814
Bradykinesia	119.87	20.29	45	11721	7998	79724624
Muscle rigidity	115.17	20.29	57	11709	19825	79712797
Tremor	102.85	20.29	126	11640	169957	79562665
Dystonia	99.75	20.29	53	11713	21346	79711276
Stoma site discharge	97.05	20.29	28	11738	2181	79730441
Resting tremor	93.08	20.29	25	11741	1496	79731126
Akinesia	89.94	20.29	29	11737	3283	79729339
Sudden onset of sleep	87.10	20.29	20	11746	624	79731998
Colitis microscopic	74.87	20.29	35	11731	10733	79721889
Dementia	64.44	20.29	42	11724	24617	79708005
Compulsive shopping	62.36	20.29	16	11750	800	79731822
Agitation	62.03	20.29	75	11691	99640	79632982
Nocturia	61.27	20.29	33	11733	13648	79718974
Jealous delusion	59.69	20.29	13	11753	317	79732305
Abnormal behaviour	58.21	20.29	46	11720	36375	79696247
Supine hypertension	56.45	20.29	13	11753	411	79732211
Balance disorder	56.09	20.29	71	11695	98786	79633836
Drug interaction	55.29	20.29	160	11606	415023	79317599
Autonomic nervous system imbalance	55.09	20.29	22	11744	4608	79728014
Cogwheel rigidity	52.35	20.29	19	11747	3069	79729553
Hyperkinesia	50.82	20.29	18	11748	2711	79729911
Stereotypy	50.68	20.29	14	11752	931	79731691
Stoma site erythema	50.27	20.29	16	11750	1737	79730885
Rapid eye movement sleep behaviour disorder	50.02	20.29	12	11754	454	79732168
Marasmus	49.51	20.29	14	11752	1014	79731608
Anxiety	48.85	20.29	111	11655	248401	79484221
Gait disturbance	48	20.29	99	11667	207407	79525215
Somnolence	47.26	20.29	107	11659	238874	79493748
Fracture	47.08	20.29	33	11733	21768	79710854
Device dislocation	46.29	20.29	35	11731	25935	79706687
Hyperthermia	45.37	20.29	30	11736	18007	79714615
Pleurothotonus	44.60	20.29	16	11750	2500	79730122
Psychotic disorder	43.22	20.29	41	11725	41361	79691261
Disturbance in attention	43.21	20.29	45	11721	50756	79681866
Choking	42.79	20.29	25	11741	12076	79720546
Mesenteric artery thrombosis	41.40	20.29	11	11755	631	79731991
Aggression	41.32	20.29	44	11722	50914	79681708
Obsessive-compulsive personality disorder	39.99	20.29	8	11758	127	79732495
Sleep talking	39.85	20.29	12	11754	1084	79731538
Paraphilia	38.95	20.29	7	11759	60	79732562
Speech disorder	38.92	20.29	44	11722	54401	79678221
Compulsive hoarding	38.35	20.29	7	11759	66	79732556
Dysphagia	37.80	20.29	66	11700	122070	79610552
Psychomotor hyperactivity	37.54	20.29	26	11740	16823	79715799
Neuroleptic malignant syndrome	36.07	20.29	31	11735	27528	79705094
Stoma site infection	35.99	20.29	12	11754	1508	79731114
Impulsive behaviour	35.27	20.29	14	11752	2886	79729736
Syncope	35.06	20.29	80	11686	179369	79553253
Oesophageal achalasia	34.59	20.29	10	11756	784	79731838
Presyncope	34.26	20.29	36	11730	41018	79691604
Pneumonia aspiration	33.16	20.29	45	11721	66922	79665700
Therapeutic product effect variable	32.71	20.29	12	11754	1997	79730625
Altered state of consciousness	32.32	20.29	36	11730	43786	79688836
Sleep attacks	31.86	20.29	7	11759	178	79732444
Micturition urgency	31.73	20.29	21	11745	12620	79720002
Abnormal dreams	31.19	20.29	20	11746	11392	79721230
Stoma site hypergranulation	30.49	20.29	8	11758	437	79732185
Blood lactic acid	30.18	20.29	8	11758	455	79732167
Disorientation	29.30	20.29	41	11725	62735	79669887
Death	29.05	20.29	162	11604	566352	79166270
Toxicity to various agents	28.95	20.29	13	11753	421527	79311095
Parkinsonian gait	28.62	20.29	9	11757	939	79731683
Hyperpyrexia	28.13	20.29	15	11751	6077	79726545
Delirium	27.84	20.29	47	11719	84580	79648042
Serum serotonin increased	27.83	20.29	7	11759	323	79732299
Cognitive disorder	27.32	20.29	42	11724	69884	79662738
Middle insomnia	27.19	20.29	21	11745	16048	79716574
Coronary artery dissection	26.96	20.29	9	11757	1135	79731487
Poor quality sleep	26.61	20.29	24	11742	22698	79709924
Parkinsonism	26.61	20.29	21	11745	16563	79716059
Compulsions	26.35	20.29	7	11759	401	79732221
Anticholinergic syndrome	25.91	20.29	12	11754	3599	79729023
Nightmare	25.83	20.29	25	11741	25836	79706786
Hip fracture	25.71	20.29	27	11739	30734	79701888
Obsessive-compulsive disorder	25.71	20.29	14	11752	5913	79726709
Drooling	25.69	20.29	14	11752	5920	79726702
Dementia with Lewy bodies	25.41	20.29	8	11758	838	79731784
Gastrointestinal motility disorder	25.28	20.29	14	11752	6108	79726514
Off label use	25.15	20.29	61	11705	907154	78825468
Micturition disorder	24.66	20.29	12	11754	4016	79728606
Loss of consciousness	24.50	20.29	67	11699	167876	79564746
Restlessness	24.17	20.29	32	11734	46460	79686162
Dizziness postural	23.82	20.29	17	11749	11532	79721090
Diarrhoea	23.77	20.29	60	11706	880429	78852193
Intermittent claudication	23.26	20.29	11	11755	3460	79729162
Psychotic symptom	22.64	20.29	10	11756	2687	79729935
Autonomic neuropathy	22.53	20.29	9	11757	1886	79730736
Reduced facial expression	22.40	20.29	10	11756	2755	79729867
Rash	22.07	20.29	32	11734	578326	79154296
Swelling	21.91	20.29	3	11763	216708	79515914
Thunderclap headache	21.72	20.29	6	11760	399	79732223
Hyperhidrosis	21.66	20.29	60	11706	151432	79581190
Panic attack	21.58	20.29	22	11744	24194	79708428
Orthostatic hypertension	21.32	20.29	7	11759	838	79731784
Device occlusion	21.16	20.29	16	11750	11850	79720772
Stoma site pain	21.15	20.29	8	11758	1450	79731172
Wrong device used	21.03	20.29	4	11762	48	79732574
Insomnia	20.56	20.29	81	11685	245089	79487533

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N04BD02	NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Monoamine oxidase B inhibitors
FDA MoA	N0000000184	Monoamine Oxidase Inhibitors
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D008996	Monoamine Oxidase Inhibitors
MeSH PA	D018696	Neuroprotective Agents
MeSH PA	D020011	Protective Agents
FDA EPC	N0000175744	Monoamine Oxidase Inhibitor
CHEBI has role	CHEBI:38623	monoamine oxidase inhibitors
CHEBI has role	CHEBI:63726	neuroprotective agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Parkinson's disease	indication	49049000	DOID:14330
Dyskinesia	contraindication	9748009
Bipolar disorder	contraindication	13746004	DOID:3312
Orthostatic hypotension	contraindication	28651003
Hypertensive disorder	contraindication	38341003	DOID:10763
Epilepsy	contraindication	84757009	DOID:1826
Disease of liver	contraindication	235856003	DOID:409
Pheochromocytoma	contraindication	302835009
Malignant melanoma	contraindication	372244006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.54	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 0.5MG BASE	AZILECT	TEVA	N021641	May 16, 2006	RX	TABLET	ORAL	7815942	Aug. 27, 2027	TREATMENT OF PARKINSONS DISEASE
EQ 1MG BASE	AZILECT	TEVA	N021641	May 16, 2006	RX	TABLET	ORAL	7815942	Aug. 27, 2027	TREATMENT OF PARKINSONS DISEASE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Amine oxidase [flavin-containing] B	Enzyme	P27338	AOFB_HUMAN	INHIBITOR	Ki	6.15	CHEMBL	CHEMBL
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN		IC50	7.72	CHEMBL
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	8.85	CHEMBL
Amine oxidase [flavin-containing] A	Enzyme	P21397	AOFA_HUMAN		Ki	5.01	CHEMBL
Cholinesterase	Enzyme	P06276	CHLE_HUMAN		IC50	5.32	CHEMBL
Amine oxidase [flavin-containing] B	Enzyme		AOFB_RAT		IC50	8.36	CHEMBL
Amine oxidase [flavin-containing] A	Enzyme		AOFA_RAT		IC50	6.39	CHEMBL

External reference:

ID	Source
4025261	VUID
N0000179514	NUI
D02562	KEGG_DRUG
136236-50-5	SECONDARY_CAS_RN
161735-79-1	SECONDARY_CAS_RN
4025261	VANDF
4025262	VANDF
C0525678	UMLSCUI
CHEBI:63620	CHEBI
RAU	PDB_CHEM_ID
CHEMBL887	ChEMBL_ID
DB01367	DRUGBANK_ID
CHEMBL1201142	ChEMBL_ID
CHEMBL1235738	ChEMBL_ID
3052776	PUBCHEM_CID
7151	INN_ID
C031967	MESH_SUPPLEMENTAL_RECORD_UI
6641	IUPHAR_LIGAND_ID
003N66TS6T	UNII
134748	RXNORM
162358	MMSL
20417	MMSL
70623	MMSL
d05612	MMSL
010775	NDDF
010776	NDDF
418734001	SNOMEDCT_US
419010007	SNOMEDCT_US
734664007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3060	TABLET	0.50 mg	ORAL	NDA authorized generic	29 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3060	TABLET	0.50 mg	ORAL	NDA authorized generic	29 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3060	TABLET	0.50 mg	ORAL	NDA authorized generic	29 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3061	TABLET	1 mg	ORAL	NDA authorized generic	29 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3061	TABLET	1 mg	ORAL	NDA authorized generic	29 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3061	TABLET	1 mg	ORAL	NDA authorized generic	29 sections
Rasagiline Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1270	TABLET	0.50 mg	ORAL	ANDA	30 sections
Rasagiline Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1270	TABLET	0.50 mg	ORAL	ANDA	30 sections
Rasagiline Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1271	TABLET	1 mg	ORAL	ANDA	30 sections
Rasagiline Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1271	TABLET	1 mg	ORAL	ANDA	30 sections
Rasagiline	Human Prescription Drug Label	1	16714-770	TABLET	0.50 mg	ORAL	ANDA	29 sections
Rasagiline	Human Prescription Drug Label	1	16714-771	TABLET	1 mg	ORAL	ANDA	29 sections
Rasagiline Mesylate	Human Prescription Drug Label	1	23155-746	TABLET	0.50 mg	ORAL	ANDA	29 sections
Rasagiline Mesylate	Human Prescription Drug Label	1	23155-747	TABLET	1 mg	ORAL	ANDA	29 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	42291-779	TABLET	0.50 mg	ORAL	NDA authorized generic	29 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	42291-779	TABLET	0.50 mg	ORAL	NDA authorized generic	29 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	42291-780	TABLET	1 mg	ORAL	NDA authorized generic	29 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	42291-780	TABLET	1 mg	ORAL	NDA authorized generic	29 sections
RASAGILINE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-220	TABLET	0.50 mg	ORAL	ANDA	29 sections
RASAGILINE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-221	TABLET	1 mg	ORAL	ANDA	29 sections
Azilect	HUMAN PRESCRIPTION DRUG LABEL	1	43353-015	TABLET	1 mg	ORAL	NDA	30 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	47781-683	TABLET	0.50 mg	ORAL	ANDA	27 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	47781-683	TABLET	0.50 mg	ORAL	ANDA	27 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	47781-690	TABLET	1 mg	ORAL	ANDA	27 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	47781-690	TABLET	1 mg	ORAL	ANDA	27 sections
Azilect	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6206	TABLET	1 mg	ORAL	NDA	30 sections
Rasagiline	Human Prescription Drug Label	1	67877-259	TABLET	0.50 mg	ORAL	ANDA	29 sections
Rasagiline	Human Prescription Drug Label	1	67877-259	TABLET	0.50 mg	ORAL	ANDA	29 sections
Rasagiline	Human Prescription Drug Label	1	67877-260	TABLET	1 mg	ORAL	ANDA	29 sections
Rasagiline	Human Prescription Drug Label	1	67877-260	TABLET	1 mg	ORAL	ANDA	29 sections